Maven Securities LTD Makes New $40,000 Investment in Unity Biotechnology, Inc. (NASDAQ:UBX)

Maven Securities LTD purchased a new position in shares of Unity Biotechnology, Inc. (NASDAQ:UBX – Get Rating) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 100,000 shares of the company’s stock, valued at approximately $40,000. Maven Securities LTD owned approximately 0.70% of Unity Biotechnology as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also made changes to their positions in UBX. Virtu Financial LLC boosted its holdings in shares of Unity Biotechnology by 25.4% during the second quarter. Virtu Financial LLC now owns 62,640 shares of the company’s stock worth $35,000 after purchasing an additional 12,681 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new position in Unity Biotechnology in the third quarter valued at $64,000. State Street Corp boosted its holdings in Unity Biotechnology by 32.4% in the third quarter. State Street Corp now owns 172,640 shares of the company’s stock valued at $68,000 after acquiring an additional 42,200 shares during the last quarter. Parkman Healthcare Partners LLC acquired a new position in Unity Biotechnology in the third quarter valued at $160,000. Finally, ExodusPoint Capital Management LP acquired a new position in Unity Biotechnology in the third quarter valued at $201,000.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the company. Mizuho reduced their target price on Unity Biotechnology from $80.00 to $12.00 and set a “buy” rating on the stock in a report on Wednesday, November 16th. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Unity Biotechnology in a report on Wednesday, February 15th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $34.50.

Unity Biotechnology Trading Up 6.1 %

Shares of UBX opened at $4.17 on Wednesday. The stock’s 50-day moving average is $4.25 and its two-hundred day moving average is $3.87. The stock has a market cap of $59.17 million, a PE ratio of -0.51 and a beta of 0.79. Unity Biotechnology, Inc. has a 12 month low of $2.09 and a 12 month high of $18.50. The company has a debt-to-equity ratio of 0.17, a current ratio of 6.12 and a quick ratio of 6.12.

Unity Biotechnology Company Profile

(Get Rating)

Unity Biotechnology, Inc operates as a biotechnology company. The firm is developing a portfolio of programs like biological mechanisms implicated in diseases of aging, and also senolytic programs in ophthalmologic and neurologic disorders. The company was founded by Nathaniel Eames David, Jan van Deursen, Judith Campisi, and Daohong Zhou on March 30, 2009 and is headquartered in South San Francisco, CA.